OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+30.79%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$283M
AUM Growth
+$283M
(+18%)
Cap. Flow
-$30.6M
Cap. Flow
% of AUM
-10.84%
Top 10 Holdings %
Top 10 Hldgs %
64.14%
Holding
48
New
7
Increased
13
Reduced
5
Closed
14
Top Buys
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
$5.36M |
| 2 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
$4.17M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$4.12M |
| 4 |
Insmed
INSM
|
$3.75M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
$3.21M |
Top Sells
| 1 |
Synlogic
SYBX
|
$17.1M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$10.1M |
| 3 |
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
|
$6.92M |
| 4 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$5.07M |
| 5 |
Prothena Corp
PRTA
|
$4.6M |
Sector Composition
| 1 | Healthcare | 94.45% |
| 2 | Communication Services | 0.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
1
DELISTED
Blueprint Medicines
BPMC
| $51.2M | 18.11% | 735,000 -145,000 | -16% | -$10.1M |
|
2
Axogen
AXGN
$743M
| $38.1M | 13.48% | 1,970,000 | – | – |
|
3
FibroGen
FGEN
$47.8M
| $19.4M | 6.85% | 360,000 | – | – |
|
|
IMMU
4
DELISTED
Immunomedics Inc
IMMU
| $12.6M | 4.44% | 898,800 -1,200 | -0.1% | -$16.8K |
|
|
LOXO
5
DELISTED
Loxo Oncology, Inc
LOXO
| $12M | 4.23% | 130,000 | – | – |
|
6
Codexis
CDXS
$246M
| $11.3M | 4% | 1,700,600 +230,600 | +16% | +$1.53M |
|
|
CORI
7
DELISTED
Corium International, Inc.
CORI
| $10.2M | 3.6% | 920,000 +205,000 | +29% | +$2.27M |
|
|
MNTA
8
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $9.25M | 3.27% | 500,000 +50,000 | +11% | +$925K |
|
9
Sangamo Therapeutics
SGMO
$157M
| $8.7M | 3.08% | 580,000 | – | – |
|
10
Agios Pharmaceuticals
AGIO
$2.19B
| $8.68M | 3.07% | 130,000 | – | – |
|
11
CytomX Therapeutics
CTMX
$336M
| $8.18M | 2.89% | 450,000 -10,000 | -2% | -$182K |
|
|
SBBP
12
DELISTED
Strongbridge Biopharma plc.
SBBP
| $8.14M | 2.88% | 1,180,000 | – | – |
|
|
EGRX
13
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $7.75M | 2.74% | 130,000 +70,000 | +117% | +$4.17M |
|
|
CMRX
14
DELISTED
Chimerix, Inc.
CMRX
| $7.37M | 2.6% | 1,403,000 +123,000 | +10% | +$646K |
|
|
FOMX
15
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $6.34M | 2.24% | 1,142,000 +7,000 | +0.6% | +$38.8K |
|
16
Xoma
XOMA
$392M
| $6.29M | 2.23% | 320,200 +3,000 | +0.9% | +$59K |
|
17
Theravance Biopharma
TBPH
$699M
| $6.16M | 2.18% | 180,000 | – | – |
|
|
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
| $5.36M | 1.89% | +665,000 | New | +$5.36M |
|
|
BOLD
19
DELISTED
Audentes Therapeutics, Inc
BOLD
| $5.04M | 1.78% | 180,000 +30,000 | +20% | +$840K |
|
|
20
Synlogic
SYBX
$17M
| $4.75M | 1.68% | 250,000 -898,100 | -78% | -$17.1M |
|
21
Enanta Pharmaceuticals
ENTA
$180M
| $4.68M | 1.66% | 100,000 | – | – |
|
|
DCPH
22
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $4.12M | 1.46% | +217,000 | New | +$4.12M |
|
23
Ardelyx
ARDX
$1.53B
| $3.92M | 1.39% | 700,000 +153,500 | +28% | +$860K |
|
|
XLRN
24
DELISTED
Acceleron Pharma Inc.
XLRN
| $3.79M | 1.34% | 101,500 +1,500 | +2% | +$56K |
|
|
25
Insmed
INSM
$28.8B
| $3.75M | 1.32% | +120,000 | New | +$3.75M |
|